PhotoCure's Metvix: Creating a New Market
Executive SummaryNorway's PhotoCure is one of the few European biotech companies with a marketed product. Skin cancer photodynamic therapy Metvix PDT has already been launched in Scandinavia, and more recently by partner Galderma in Germany and the UK. Other PDT firms have struggled to educate physicians to accept a new kind of treatment-and thereby recoup the costs attached. PhotoCure is hoping that Metvix's improved efficacy and cosmetic advantages will help it create a market for PDT products.
You may also be interested in...
Drug pricing and access issues expose the pharmaceutical sector especially acutely to calls for companies to meet ethical and social goals, alongside commercial ones. Digital is up-ending pharma’s processes, its workplaces and its consumers. R&D productivity is spluttering. Amid this turmoil, CEOs highlight company culture – the way an organization behaves – as a crucial ingredient for success. But what is a “right” culture? Organizational culture is neither static nor singular. It is continuously influenced by acquisitions, markets, new technologies and new generations. And pharma’s history suggests that culture change cannot happen without sufficient people change.
ICER’s influence on drug pricing, and policy, is growing. Spotlighting the worst drug price rises is one recent example.